Development of Hepatotoxicity in HIV Patients Switching at Least One Protease Inhibitor

In order to evaluate the occurrence of hepatotoxicity in patients treated with antiretroviral therapy (ART) who switch protease inhibitor (PI), and the role of viral hepatitis in its development, researchers performed a retrospective study on 182 HIV patients treated with ART for 24 months.

The presence of hepatitis viruses and alanine transaminase levels were evaluated.

Hepatotoxicity developed in a low number of subjects without co-infection, but was significantly higher in co-infected patients (14/51 versus 62/131, P = 0.01). Ritonavir (Norvir) was associated with higher rates of severe hepatotoxicity in the co-infected group.

Patients presenting any problems related to ART, including the development of hepatotoxicity, continued therapy by switching PI.

The occurrence of hepatotoxicity with second/third choice PIs, including ritonavir, remained stable.

The authors conclude, “Our results suggest that switching PI does not increase the occurrence of drug-related liver toxicity.”

02/16/05

Reference
A Aceti and others. Development of hepatotoxicity in HIV patients switching at least one protease inhibitor. International Journal of STD & AIDS 16(2): 148-152. February 2005.

Link to Index of All HIV and AIDS Articles by Topic